Magic bullets for the 21st century: The reemergence of immunotherapy for multi- and pan-resistant microbes

Journal of Antimicrobial Chemotherapy

Volumn 67, Issue 12, 2012, Pages 2785-2787

  Roux, Damien ^a   Pier, Gerald B ^a   Skurnik, David ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

Antibiotic resistance; Broad spectrum vaccines; PNAG; Poly N acetylglucosamine

Indexed keywords

MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY F598; N ACETYLGLUCOSAMINE; POLY BETA 1,6 N ACETYLGLUCOSAMINE; UNCLASSIFIED DRUG;

ACINETOBACTER BAUMANNII; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; ARTICLE; BACTERIAL VIRULENCE; BURKHOLDERIA CEPACIA COMPLEX; DRUG SAFETY; ESCHERICHIA COLI; IMMUNOTHERAPY; NONHUMAN; PHASE 2 CLINICAL TRIAL (TOPIC); PROTEIN EXPRESSION; RANDOMIZED CONTROLLED TRIAL (TOPIC); STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTIBODIES, BACTERIAL; ANTIBODIES, MONOCLONAL; BACTERIA; BACTERIAL INFECTIONS; BETA-GLUCANS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84869423294     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dks335     Document Type: Article

References (23)

1. Gaynes RP. Germ Theory: Medical Pioneers in Infectious Diseases. Washington, DC: ASM Press, 2011.
2. Livermore DM. Discovery research: the scientific challenge of finding new antibiotics. J Antimicrob Chemother 2011; 66: 1941-4.
3. Skurnik D, Nucci A, Ruimy R et al. Emergence of carbapenem-resistant Hafnia: the fall of the last soldier. Clin Infect Dis 2010; 50: 1429-31.
4. Kelly-Quintos C, Cavacini LA, Posner MR et al. Characterization of the opsonic and protective activity against Staphylococcus aureus of fully human monoclonal antibodies specific for the bacterial surface polysaccharide poly-N-acetylglucosamine. Infect Immun 2006; 74: 2742-50.
5. Vlock D, Lee JC, Kropec A et al. Pre-clinical and initial Phase I evaluations of a fully human monoclonal antibody directed against the PNAG surface polysaccharide on Staphylococcus aureus. In: Abstracts of the Fiftieth Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, USA, 2010. Abstract G1-1654, p. 329. American Society for Microbiology, Washington, DC, USA.
6. Niessen LW, ten Hove A, Hilderink H et al. Comparative impact assessment of child pneumonia interventions. Bull World Health Organ 2009; 87: 472-80.
7. Bernatoniene J, Finn A. Advances in pneumococcal vaccines: advantages for infants and children. Drugs 2005; 65: 229-55.
8. Gasparini R, Panatto D. Meningococcal glycoconjugate vaccines. Hum Vaccin 2011; 7: 170-82.
9. Swingler G, Fransman D, Hussey G. Conjugate vaccines for preventing Haemophilus influenzae type b infections. Cochrane Database Syst Rev 2003; issue 4: CD001729.
10. Lin FY, Ho VA, Khiem HB et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. N Engl J Med 2001; 344: 1263-9.
11. McKenney D, Pouliot KL, Wang Y et al. Broadly protective vaccine for Staphylococcus aureus based on an in vivo-expressed antigen. Science 1999; 284: 1523-7.
12. Cerca N, Maira-Litran T, Jefferson KK et al. Protection against Escherichia coli infection by antibody to the Staphylococcus aureus poly-N-acetylglucosamine surface polysaccharide. Proc Natl Acad Sci USA 2007; 104: 7528-33.
13. Skurnik D, Davis MR Jr, Benedetti D et al. Targeting pan-resistant bacteria with antibodies to a broadly conserved surface polysaccharide expressed during infection. J Infect Dis 2012; 205: 1709-18.
14. Bentancor LV, O'Malley JM, Bozkurt-Guzel C et al. Poly-N-acetyl-b-(1-6)-glucosamine is a target for protective immunity against Acinetobacter baumannii infections. Infect Immun 2012; 80: 651-6.
15. Cramton SE, Gerke C, Schnell NF et al. The intercellular adhesion (ica) locus is present in Staphylococcus aureus and is required for biofilm formation. Infect Immun 1999; 67: 5427-33.
16. Wang X, Preston JF III, Romeo T. The pgaABCD locus of Escherichia coli promotes the synthesis of a polysaccharide adhesin required for biofilm formation. J Bacteriol 2004; 186: 2724-34.
17. Kropec A, Maira-Litran T, Jefferson KK et al. Poly-N-acetylglucosamine production in Staphylococcus aureus is essential for virulence in murine models of systemic infection. Infect Immun 2005; 73: 6868-76.
18. Skurnik D, Kropec A, Roux D et al. Natural antibodies in normal human sera inhibit Staphylococcus aureus capsular polysaccharide vaccine efficacy. Clin Infect Dis 2012; doi:10.1093/cid/cis624.
19. Skurnik D, Merighi M, Grout M et al. Animal and human antibodies to distinct Staphylococcus aureus antigens mutually neutralize opsonic killing and protection in mice. J Clin Invest 2010; 120: 3220-33.
20. Maira-Litran T, Kropec A, Goldmann DA et al. Comparative opsonic and protective activities of Staphylococcus aureus conjugate vaccines containing native or deacetylated staphylococcal poly-N-acetyl-b-(1-6)-glucosamine. Infect Immun 2005; 73: 6752-62.
21. Gening ML, Maira-Litran T, Kropec A et al. Synthetic b-(1 6)-linked N-acetylated and nonacetylated oligoglucosamines used to produce conjugate vaccines for bacterial pathogens. Infect Immun 2010; 78: 764-72.
22. Choi AH, Slamti L, Avci FY et al. The pgaABCD locus of Acinetobacter baumannii encodes the production of poly-b-1-6-N-acetylglucosamine, which is critical for biofilm formation. J Bacteriol 2009; 191: 5953-63.
23. Yakandawala N, Gawande PV, LoVetri K et al. Characterization of the poly-b-1,6-N-acetylglucosamine polysaccharide component of Burkholderia biofilms. Appl Environ Microbiol 2011; 77: 8303-9.